Bringing the fundamentals into focus…
Back to Artiva Biotherapeutics, Inc.
How Artiva Biotherapeutics, Inc. stacks up
ARTV · against 209 other Healthcare companies of similar size
Growth
8/ 100
Near the bottom of its peers.
Ranked #184 of 210 · scores higher than 11% of peers
Bars: peers in each 10-point band of the growth score31 peers with a growth score of 0–9, including ARTV · Click a bar to see the companies
Why growth scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth, which is weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 100% of peers. Revenue growth: -100.0% vs peer median 6.1%
- 3-year revenue growth is not reported, so it is left out of the score.
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = ARTV, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ARTV | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 221 reported | -100.0% | 3.9% | 0% | 33% | |
| Earnings per share growthHigher is better · 86 reported | Not reported | 2.9% | — | — | 33% |
| 3-year revenue growthHigher is better · 203 reported | Not reported | 3.9% | — | — | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around ARTV| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 1 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 4 | 5.7B TWD (≈$177M) | 98 | 65 | |
| 4 | 217M AUD (≈$143M) | 98 | 43 | |
| 180 | 354M USD | 9 | 13 | |
| 184 | 2.5B CNY (≈$349M) | 8 | 27 | |
| 184 | 1.9B CNY (≈$262M) | 8 | 24 | |
| 184 | 8.1B TWD (≈$251M) | 8 | 69 | |
| 184 | 205M USD | 8 | 36 | |
| 184 | 285M USD | 8 | 38 | |
| 189 | 2.7B CNY (≈$383M) | 7 | 24 | |
| 189 | 2.7B CNY (≈$381M) | 7 | 28 | |
| 189 | 35.2B JPY (≈$240M) | 7 | 12 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score